Assays and therapies for latent viral infection

Details Assays and therapies for latent viral infection Assays and therapies for latent viral infection

2006-07-18

2006-07-18

Salimi, Ali R. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S069100, C435S007100, C435S235100

Reexamination Certificate

active

07078173

ABSTRACT:
Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

REFERENCES:
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4675382 (1987-06-01), Murphy
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 5637454 (1997-06-01), Harley
patent: 5906820 (1999-05-01), Bacha
patent: WO 98/30586 (1998-07-01), None
patent: WO 99/02550 (1999-01-01), None
Murray et al . Journal of Exp. Medicine, Jul. 1992, vol. 176, pp. 157-168.
Adelstein, et al.,Nucl. Med. Biol.14: 165-169 (1987).
Alford,Antiviral agents and viral diseases of man2nded. Raven Press: New York, pp. 433-486 (1984).
Alsbaugh, et al.,Arthr. Rheum.19: 711-719 (1976).
Alsbaugh, et al.,J. Clin. Invest.67: 1134-1140 (1981).
Ashley, et al., “Detection of asymptomatic herpes simplex virus infections after vaccination,”J. Virol.61: 253-258 (1987).
Babcock, et al.,J. Exp. Med.190: 567-576 (1999).
Barnes,Pharma Weekly1: 11 (1995).
Bell, et al.,J. Rheumatol.11: 277-281 (1984).
Bray, et al., “Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein,”Arch. Neurol.42: 1798-1804 (1992).
Bray, et al.,Arch. Neurol.40: 406-408 (1983).
Browning, et al.,J. Immunol.143: 1859-1867 (1989).
Calderwood, et al., “Nucleotide sequence of the Shiga-like toxin genes ofEscherichia coli,” Proc. Natl. Acad. Sci. USA84: 4364-4368 (1987).
Catalano, et al., “Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis,”Proc. Natl. Acad. Sci USA76: 5825-5828 (1979).
Chen, et al.,J. Biol. Chem.266: 18237-18243 (1991).
Colombatti, et al.,J. Biol. Chem.261: 3030-3035 (1986).
Dalldorf, et al., “The Lymphomas of Brazilian Children,”J. Am. Med. Assn.208: 1365-8 (1969).
Deacon, et al., “Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome,”J. Pathol.163: 351-360 (1991).
Deacon, et al., “Frequency of EBV DNA Detection in Sjogren's Syndrome,”Am J. Med.92: 453-454 (1992).
Debrus, et al., “Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency,”J. Virol.69: 3240-3245 (1995).
Dedrick, et al.,Cancer Treat. Rep.62: 1-11 (1978).
Deleers, et al.,FEBS Lett.160: 82-86 (1983).
Diener, et al., “Specific Immunosuppression by Immunotoxins Containing Daunomycin,”Science231 (4734): 148-150 (1986).
Digard, et al., “Functional analysis of the herpes simplex virus UL42 protein,”J. Virol.67: 1159-1168 (1993).
Dittmer, et al., “A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus,”J. Virol.72: 8309-8315 (1998).
Donahue, et al.,Arch. Int. Med.155: 1605-1609 (1995).
Elek, et al.,Lancet1: 1-5 (1974).
Ertl, et al., “Physical and functional interaction of human cytomegalovirus DNA polymerase and its accessory protein (ICP36) expressed in insect cells,”J. Virol.66: 4126-33 (1992).
Ferrel, et al.,J. Clin. Invest.67: 681-687 (1981).
Finerty, et al., “Immunization of Cottontop Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum,”Vaccine12: 1180-1184 (1994).
Finerty, et al., “Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector,”J. Gen. Virol.73: 449-453 (1992).
Fox, “Sjogren's Syndrome,”Current Opin. Rheum.7: 409-416 (1995).
Fox, et al., “Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome,”J. Immunol.137: 3162-3168 (1986).
Fox, et al., “Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis,”J. Rheumatol.19: 18-24 (1992).
Glassy, et al.,J. Immunol. Methods81: 115 (1985).
Goodrich, et al.,Ann. Intern. Med.118:173-178 (1993).
Gray, et al., “Cloning, nucleotide sequence, and expression inEscherichia coliof the exotoxin A structural gene ofPseudomonas aeruginosa,” Proc. Natl. Acad. Sci. USA81:2645-2649 (1984).
Greenwood, et al.,Biochem. J.89: 114-123 (1963).
Griffiths, et al.,Cancer Res.51: 4594-4602 (1991).
Gu, et al., “First E8V Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen,”Dev. Biol. Stand.84: 171-177 (1995).
Gutierrez, et al., “Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia,”Cancer Res.56: 969-972 (1996).
Haahr, et al., “A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease,”Ann. N. Y. Acad. Sci.724: 148-156 (1996).
Halpern, et al.,J. Nucl. Med.29: 1688-1696 (1988).
Harley & James, “Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers,”Arthr. Rheum.42(8): 1782-1783 (1999).
Heslop, et al., “Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes,”Nature Med.2: 551-555 (1996).
Hiskey,Peptides3: 137 (1981).
Ho,Cytomegalovirus, biology and infection: current topics in infectious diseasePlenum Press: New York, pp. 105-118 (1982).
Hoch, et al., “Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes,”Proc. Natl. Acad. Sci. USA82: 1692-1696 (1985).
Hwang, et al.,Cell48: 129-136 (1987).
Inoue, et al., “Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis,”J. Infect. Dis.164:22-28 (1991).
Ishii, et al., “Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection,”Immunol. Cell Biol.73: 463-468 (1995).
James & Harley, “Linear Epitope Mapping of an Sm B/B′ Polypeptide,”J. Immunol.148: 2074-2079 (1992).

Affiliated with

Also associated with

Rating

Assays and therapies for latent viral infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Assays and therapies for latent viral infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays and therapies for latent viral infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3576470